New Antiproliferative Pyrazole/Quinoline Hybrids: Design, Synthesis, and Biological Evaluation as EGFR Inhibitors

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Development of novel antiproliferative agents is crucial for cancer therapy.
• Pyrazole and quinoline scaffolds are recognized for their biological activities.
• Targeting specific pathways like EGFR is a key strategy in cancer treatment.

Purpose of the Study:

• To synthesize and evaluate novel pyrazole/quinoline hybrids as potential antiproliferative agents.
• To assess the efficacy of these hybrids against a panel of human cancer cell lines.
• To investigate the inhibitory potential against the Epidermal Growth Factor Receptor (EGFR).

Main Methods:

• Synthesis of pyrazole/quinoline hybrids (compounds 11a-n).
• In vitro antiproliferative activity assessment using IC50 values against HT-29, A-549, Panc-1, and MCF-7 cell lines.
• In vitro EGFR inhibition assay and molecular docking studies.

Main Results:

• Several hybrids (11c, 11d, 11h, 11i, 11k) exhibited potent antiproliferative activity (IC50: 36-61 nM).
• Hybrid 11i demonstrated significant EGFR inhibition (IC50: 87 nM), comparable to erlotinib (IC50: 80 nM).
• Molecular docking studies supported the observed EGFR inhibitory activity.

Conclusions:

• The synthesized pyrazole/quinoline hybrids represent promising candidates for antiproliferative drug development.
• Hybrid 11i shows particular promise as an EGFR inhibitor.
• Further investigation into these hybrids could lead to new cancer treatment strategies.